EIKN Stock News & Catalysts

FEATURED

Eikon Therapeutics to Participate in Multiple Investor Conferences in November

CEO Roger M. Perlmutter, M.D., Ph.D., to participate in Guggenheim 3rd Annual Healthcare Innovation Conference Fireside Chat and JP Morgan Biotech Call seriesCMO Roy Baynes, M.D., Ph.D., to participate in Morgan Stanley

Summary

Nov 2, 2026, 9:15 AM ·Globe Newswire

RECENT

Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress

TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile

Oct 26, 2026, 6:00 AM ·Globe Newswire

Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress

Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support potentially differentiated profile of EIK1003 in combination strategies

Oct 23, 2026, 9:15 AM ·Globe Newswire

Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress

Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and

Oct 18, 2026, 6:05 PM ·Globe Newswire

Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer

MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address

Oct 15, 2026, 8:00 AM ·Globe Newswire

Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address

Sep 3, 2026, 7:30 AM ·Globe Newswire

Eikon Therapeutics to Participate in Investor Conferences in September 2026

MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address

Aug 26, 2026, 7:30 AM ·Globe Newswire

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald

MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address

Aug 18, 2026, 4:15 PM ·Globe Newswire

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical updates for EIK1001

Aug 13, 2026, 4:02 PM ·Globe Newswire

Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma

Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following

Aug 11, 2026, 7:30 AM ·Globe Newswire

Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board

MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address

Aug 10, 2026, 7:30 AM ·Globe Newswire

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet

Jul 27, 2026, 7:30 AM ·Globe Newswire

Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress

Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4

Jul 20, 2026, 8:00 AM ·Globe Newswire

Eikon Therapeutics to Join the Russell 3000® Index

MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address

Jun 25, 2026, 4:15 PM ·Globe Newswire

Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors

MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious

Jun 8, 2026, 8:00 AM ·Globe Newswire

Eikon Therapeutics, Inc. Common Stock EIKN · News